CN112292402A - 抗肿瘤融合蛋白及其制法和应用 - Google Patents

抗肿瘤融合蛋白及其制法和应用 Download PDF

Info

Publication number
CN112292402A
CN112292402A CN201980020574.6A CN201980020574A CN112292402A CN 112292402 A CN112292402 A CN 112292402A CN 201980020574 A CN201980020574 A CN 201980020574A CN 112292402 A CN112292402 A CN 112292402A
Authority
CN
China
Prior art keywords
protein
fusion protein
gnrh
tumor
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980020574.6A
Other languages
English (en)
Other versions
CN112292402B (zh
Inventor
颜浩为
侯天全
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jilin Huirong Biotechnology Co ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN112292402A publication Critical patent/CN112292402A/zh
Application granted granted Critical
Publication of CN112292402B publication Critical patent/CN112292402B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1758—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明提供了一种抗肿瘤融合蛋白及其制法和应用。具体地，本发明提供了一种包括GnRH蛋白元件、PEA蛋白的跨膜转运区和P53蛋白元件的融合蛋白，所述融合蛋白可以高效地将p53蛋白输送到细胞核并高效引发肿瘤细胞凋亡。本发明还提供了编码所述融合蛋白的核苷酸、生产所述融合蛋白的方法以及包含所述融合蛋白的药物组合物。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201980020574.6A 2018-04-08 2019-04-08 抗肿瘤融合蛋白及其制法和应用 Active CN112292402B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018103069079 2018-04-08
CN201810306907.9A CN110357968B (zh) 2018-04-08 2018-04-08 抗肿瘤融合蛋白及其制法和应用
PCT/CN2019/081735 WO2019196790A1 (zh) 2018-04-08 2019-04-08 抗肿瘤融合蛋白及其制法和应用

Publications (2)

Publication Number Publication Date
CN112292402A true CN112292402A (zh) 2021-01-29
CN112292402B CN112292402B (zh) 2023-09-19

Family

ID=68163494

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810306907.9A Active CN110357968B (zh) 2018-04-08 2018-04-08 抗肿瘤融合蛋白及其制法和应用
CN201980020574.6A Active CN112292402B (zh) 2018-04-08 2019-04-08 抗肿瘤融合蛋白及其制法和应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201810306907.9A Active CN110357968B (zh) 2018-04-08 2018-04-08 抗肿瘤融合蛋白及其制法和应用

Country Status (2)

Country Link
CN (2) CN110357968B (zh)
WO (1) WO2019196790A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110357968A (zh) * 2018-04-08 2019-10-22 颜浩为 抗肿瘤融合蛋白及其制法和应用
CN116735878A (zh) * 2023-06-06 2023-09-12 北京三品医疗科技有限公司 多肽在诊断癌症中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116023512A (zh) * 2023-02-16 2023-04-28 浙江大学 一条靶向dna损伤修复蛋白的多肽及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
CN1966529A (zh) * 2006-06-21 2007-05-23 深圳市高科生物科技有限公司 含有促性腺激素释放素和绿脓毒素功能片段的重组毒性剂
CN101070547A (zh) * 2007-05-15 2007-11-14 中国人民解放军军事医学科学院军事兽医研究所 主动运载外源基因的重组蛋白载体PEAⅡ－HPhA及其制备方法和应用
CN101684472A (zh) * 2008-09-26 2010-03-31 中国人民解放军军事医学科学院毒物药物研究所 包含p53基因的重组融合蛋白和重组体及其用途
CN101987873A (zh) * 2009-08-07 2011-03-23 普罗特奥姆技术公司 P53融合蛋白及应用
CN103805621A (zh) * 2013-12-21 2014-05-21 中国人民解放军军事医学科学院军事兽医研究所 靶向性抗肿瘤融合蛋白质lpo的新型制备工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006029078A2 (en) * 2004-09-07 2006-03-16 The Regents Of The University Of California Targeting transducible molecules to specific cell types
CN101557817A (zh) * 2006-09-14 2009-10-14 人类基因科学公司 清蛋白融合蛋白
CN101343328B (zh) * 2008-08-25 2011-06-01 北京博翱泰生物技术有限公司 靶特异性双突变体融合蛋白质
CN101880327A (zh) * 2010-02-09 2010-11-10 沈阳药科大学 蝎镇痛抗肿瘤缬精甘肽融合体及其获得方法
CN102603897B (zh) * 2011-12-08 2014-10-08 山东省科学院生物研究所 含引导肽和GnRH-PE39KDEL的融合蛋白和核酸及其用途
EP3295945A1 (en) * 2012-03-13 2018-03-21 HLI Cellular Therapeutics, LLC Modified erythrocyte precursor cells and uses thereof
CN106117352B (zh) * 2016-07-05 2020-10-09 中国人民解放军军事医学科学院军事兽医研究所 抗A型肉毒毒素的人源单链抗体E3-scFv及其应用
CN110357968B (zh) * 2018-04-08 2023-08-25 吉林省汇融生物科技有限公司 抗肿瘤融合蛋白及其制法和应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
CN1966529A (zh) * 2006-06-21 2007-05-23 深圳市高科生物科技有限公司 含有促性腺激素释放素和绿脓毒素功能片段的重组毒性剂
CN101070547A (zh) * 2007-05-15 2007-11-14 中国人民解放军军事医学科学院军事兽医研究所 主动运载外源基因的重组蛋白载体PEAⅡ－HPhA及其制备方法和应用
CN101684472A (zh) * 2008-09-26 2010-03-31 中国人民解放军军事医学科学院毒物药物研究所 包含p53基因的重组融合蛋白和重组体及其用途
CN101987873A (zh) * 2009-08-07 2011-03-23 普罗特奥姆技术公司 P53融合蛋白及应用
CN103805621A (zh) * 2013-12-21 2014-05-21 中国人民解放军军事医学科学院军事兽医研究所 靶向性抗肿瘤融合蛋白质lpo的新型制备工艺

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JIYOON RYU等: "Intracellular delivery of p53 fused to the basic domain of HIV-1 Tat", 《MOLECULES AND CELLS》 *
贾培媛: "GnRH-p53系列融合蛋白的表达及其抗肿瘤功能研究", 《中国博士学位论文全文数据库》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110357968A (zh) * 2018-04-08 2019-10-22 颜浩为 抗肿瘤融合蛋白及其制法和应用
CN110357968B (zh) * 2018-04-08 2023-08-25 吉林省汇融生物科技有限公司 抗肿瘤融合蛋白及其制法和应用
CN116735878A (zh) * 2023-06-06 2023-09-12 北京三品医疗科技有限公司 多肽在诊断癌症中的应用
CN116735878B (zh) * 2023-06-06 2024-03-19 北京三品医疗科技有限公司 多肽在诊断癌症中的应用

Also Published As

Publication number Publication date
WO2019196790A1 (zh) 2019-10-17
CN112292402B (zh) 2023-09-19
CN110357968A (zh) 2019-10-22
CN110357968B (zh) 2023-08-25

Similar Documents

Publication Publication Date Title
CN100424175C (zh) ErbB-3 用于肿瘤治疗的方法和组合物
CN112292402B (zh) 抗肿瘤融合蛋白及其制法和应用
EA023005B1 (ru) Слитый белок против злокачественных новообразований
JP6574175B2 (ja) 細胞透過性ペプチド、及びそれを含むコンジュゲート
US10259852B2 (en) Conjugate comprising P21 protein for the treatment of cancer
EA025830B1 (ru) Слитый белок против злокачественной опухоли
WO2014063495A1 (zh) 一种rTRAIL突变体及其海兔毒素偶联物
CN106589131B (zh) 融合蛋白4D5Fv-PE25及其制备方法和用途
CA2610281A1 (en) Therapeutic agent for cancer
AU2011200901B2 (en) Methods and Agents for the Treatment of Cancer
EP0927250A1 (en) HUMAN POLYHOMEOTIC 1(hphl) ACTS AS A TUMOR SUPPRESSOR
EP2609430A1 (en) Recombinant fc-fusion protein of the fifth fibronectin type iii domain of dcc
CN102993314B (zh) 一种抗肿瘤融合蛋白及其制备方法和用途
CN109400711B (zh) 一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
US11566045B2 (en) Tumor targeting polypeptide and method of use thereof
WO2006090494A1 (ja) 制癌剤
GB2578390A (en) Saponin compound targeting PD-1 and application thereof
US20230226157A1 (en) Anti-tumor fusion protein, preparation method therefor and application thereof
US20220023395A1 (en) Methods of treating or preventing cancer with an agent that depletes tregs and a checkpoint inhibitor
EP2708241A1 (en) Recombinant Fc-fusion protein of the two Immunoglobulin domains of UNC5
CN110452301A (zh) 一种抗肿瘤融合蛋白及其编码多核苷酸和应用
WO2012112869A2 (en) Targeted cancer therapy using ets transcriptional inhibitors
JPH10509949A (ja) ｅｒｂＢ２−４を過剰発現する細胞に向けられた細胞毒性活性を備えた融合タンパク質
CN111732631A (zh) 一种多肽及其在制备治疗和预防肿瘤的药物中的应用
WO2011079431A1 (zh) 具有端粒酶抑制活性的融合蛋白、其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20230817

Address after: Floors 1-2, Office Building 1, Changchun Zhongbang Technology Development Co., Ltd., No. 999 Qingtianshu Street, Jingyue Development Zone, Changchun City, Jilin Province, 130117

Applicant after: Jilin Huirong Biotechnology Co.,Ltd.

Address before: 130022 Room 302, unit 2, building 6, block B, Fuao garden, Nanguan District, Changchun City, Jilin Province

Applicant before: Yan Haowei

Applicant before: Hou Tianquan

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant